Effectiveness and Safety of Zilucoplan Treatment for French Patients with Myasthenia Gravis Over 3 Months
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Feb 4, 2025
Trial Information
Current as of September 13, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment called Zilucoplan for people in France who have myasthenia gravis, a condition that causes muscle weakness, especially after being active throughout the day. The study's goal is to see if Zilucoplan can help improve muscle strength and make daily life easier for patients over a period of three months. The researchers will also keep an eye on how well patients tolerate the treatment and any side effects that may occur.
To participate in the trial, individuals need to have a confirmed diagnosis of myasthenia gravis with specific antibodies (called anti-AChR antibodies) and must be currently receiving treatment with Zilucoplan. There are no specific exclusions, meaning that if patients meet the criteria, they could be eligible to join. If you or a loved one is interested, this trial could be a valuable opportunity to explore a new treatment option that may help manage this challenging condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Confirmed diagnosis of myasthenia gravis with anti-AChR antibodies in patients treated with Zilucoplan
- Exclusion Criteria:
- • None
About Centre Hospitalier Universitaire De Nice
The Centre Hospitalier Universitaire (CHU) de Nice is a leading academic medical center located in Nice, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Nice is committed to enhancing patient care by conducting rigorous studies that explore new therapies and treatment modalities across various medical disciplines. With a focus on collaboration, the center integrates cutting-edge technology and interdisciplinary expertise to ensure the highest standards of research integrity and patient safety. CHU de Nice plays a vital role in the development of evidence-based medicine, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nice, Alpes Maritimes, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported